Related Experiment Video

Updated: Jun 4, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.4K

The effect of disopyramide therapy on functional capacity improvement in patients with obstructive hypertrophic

Arda Güler1, Yunus Emre Erata1, Ayşe İrem Demirtola2

  • 1University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkey.

International Journal of Cardiology
|December 20, 2024
PubMed

Insights

Disopyramide significantly improved functional capacity in obstructive hypertrophic cardiomyopathy (HCM) patients. A higher percentage of patients on disopyramide achieved improved NYHA class compared to controls.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart condition characterized by left ventricular outflow tract obstruction (LVOTO).
  • Obstructive HCM (HOCM) leads to symptoms and adverse outcomes, necessitating effective treatments.
  • Disopyramide, a negative inotropic agent, is utilized to alleviate LVOTO in HOCM.

Purpose of the Study:

  • To evaluate the impact of disopyramide on functional capacity in patients with HOCM.
  • To compare treatment response rates between disopyramide and standard therapies (beta-blockers or calcium channel blockers).

Main Methods:

  • Symptomatic HOCM patients were divided into disopyramide and control groups (beta-blockers/calcium channel blockers).
  • Treatment response was defined as a ≥1-stage improvement in New York Heart Association (NYHA) functional class.
  • Clinical data, NT-proBNP levels, and LVOT gradient were analyzed.

Main Results:

  • 62% of patients receiving disopyramide achieved a ≥1-stage NYHA improvement versus 26% in the control group.
  • Disopyramide use and left ventricular late gadolinium enhancement (LGE) predicted functional improvement.
  • No significant difference in overall clinical outcomes was observed, with minimal side effects from disopyramide.

Conclusions:

  • Disopyramide significantly enhances functional capacity in HOCM patients.
  • Improved accessibility to disopyramide is crucial, especially in regions with limited availability.
  • Disopyramide offers a viable therapeutic option for improving symptoms in HOCM.
Abstract

Keywords:
DisopyramideFunctional capacityHypertrophic cardiomyopathyLVOT obstruction

More Related Videos

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.3K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.7K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
339
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
315